Johnson & Johnson beats Q1 sales estimates and raises outlook

businesscompany-earnings 4 posts · 4 accounts

Johnson & Johnson reported stronger-than-expected first-quarter sales and lifted guidance, reinforcing confidence in its pharma and medtech businesses.

From the sources (4 posts)

@financialjuice

Johnson & Johnson Q1 2026 Earnings Sales $24.06b, est. $23.66b Adj EPS $2.70, est. $2.69 Adj EPS $2.70 vs. $2.77 y/y Medtech sales $8.64b, +7.7% y/y Tremfya rev $1.61b, est. $1.41b Darzalex revenue $3.96b, est. $3.84b Sees fy adj EPS $11.4

@wallstengine

$JNJ Q1’26 EARNINGS HIGHLIGHTS 🔹 Revenue: $24.06B (Est. $23.61B) 🟢; UP +9.9% YoY 🔹 Adj. EPS: $2.70 (Est. $2.68) 🟢; DOWN -2.5% YoY 🔹 Adjusted Operational Sales Growth: +5.3% YoY 🔹 Innovative Medicine: $15.43B; UP +11.2% YoY 🔹 MedTech: $8.64

@business

Johnson & Johnson reported first-quarter sales above Wall Street’s expectations and bumped up its outlook for the year

@alphasenseinc

$JNJ Earnings: - 2026 First-Quarter reported sales growth of 9.9% to $24.1 Billion with operational growth of 6.4% and adjusted operational growth of 5.3% - 2026 First-Quarter earnings per share (EPS) of $2.14 and adjusted EPS of $2.70 - C

Bitcoin ETF demand turns positive again as Wall Street holdings expand Iran shifts oil export control back to its state company after shadow-fleet disruption